DelMar Pharmaceuticals, Inc. – “Developing Targeted Therapies for Unmet Medical Needs by Harnessing Proven Cancer Medicines and Modern Biological Research”

NEW YORK, NY / ACCESSWIRE / November 10, 2015 / DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) today published a new blog post on The Chairman’s Blog, written by the Company’s Chief Executive Officer, Jeffrey Bacha. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

In his inaugural blog post, “DelMar Pharmaceuticals – Developing Targeted Therapies for Unmet Medical Needs by Harnessing Proven Cancer Medicines and Modern Biological Research,” DelMar CEO Jeffrey Bacha discusses the Company’s strategy to develop targeted medications for for cancer patients who have few or no viable treatment options. Mr. Bacha highlights the Company’s lead drug candidate VAL-083 and it’s potential to treat glioblastoma multiforme and other cancer indications. Read the full blog post from Mr. Bacha on TheChairmansBlog.com (http://www.thechairmansblog.com/delmar-pharmaceuticals/jeffrey-bacha/delmar-pharmaceuticals-developing-targeted-therapies-for-unmet-medical-needs-by-harnessing-proven-cancer-medicines-and-modern-biological-research-4/).

About DelMar Pharmaceuticals, Inc.

DelMar Pharmaceuticals, Inc. was founded to develop and commercialize new cancer therapies in indications where patients are failing or have become intolerable to modern targeted or biologic treatments. The Company’s lead drug in development, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme. VAL-083 has been extensively studied by U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action that could provide improved treatment options for patients.

About TheChairmansBlog.com

TheChairmansBlog.com is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. www.thechairmansblog.com

SOURCE: TheChairmansBlog.com

ReleaseID: 433488